Patents by Inventor Kristina L. Bondurant

Kristina L. Bondurant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer
    Patent number: 9783795
    Abstract: Peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin—are described. Since the peptides bind to more than one HLA class II protein variant, they can be used to treat cancer in most patients of a population having a variety of HLA class II alleles. The peptides can be loaded onto autologous dendritic cells of a cancer patient and infused into the patient to activate a CD4+ and CD8+ T cell response that recognizes tumor cells expressing the peptide antigen.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: October 10, 2017
    Inventors: Martin J. Cannon, Kristina L. Bondurant, Timothy J. O'Brien
  • Immunotherapeutic methods targeted toward stratum corneum chymotryptic enzyme
    Patent number: 8187587
    Abstract: The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies.
    Type: Grant
    Filed: December 26, 2007
    Date of Patent: May 29, 2012
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: Timothy J. O'Brien, Martin J. Cannon, Alessandro Santin, Kristina L. Bondurant
  • MULTI-EPITOPE PEPTIDE-LOADED DENDRITIC CELL IMMUNOTHERAPY FOR CANCER
    Publication number: 20110038895
    Abstract: The invention involves peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin. Since the peptides bind to more than one HLA class II protein variant, they can be used to treat cancer in most patients of a population having a variety of HLA class II alleles. The peptides can be loaded onto autologous dendritic cells of a cancer patient and infused into the patient to activate a CD4+ and CD8+ T cell response that recognizes tumor cells expressing the peptide antigen.
    Type: Application
    Filed: October 27, 2010
    Publication date: February 17, 2011
    Inventors: MARTIN J. CANNON, KRISTINA L. BONDURANT, TIMOTHY J. O'BRIEN
  • Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer
    Patent number: 7846446
    Abstract: The invention involves peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin. Since the peptides bind to more than one HLA class II protein variant, they can be used to treat cancer in most patients of a population having a variety of HLA class II alleles. The peptides can be loaded onto autologous dendritic cells of a cancer patient and infused into the patient to activate a CD4+ and CD8+ T cell response that recognizes tumor cells expressing the peptide antigen.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: December 7, 2010
    Assignee: Board of Trustees of the University of Arkansas
    Inventors: Martin J. Cannon, Kristina L. Bondurant, Timothy J. O'Brien
  • Immunotherapeutic methods targeted toward stratum corneum chymotryptic enzyme
    Publication number: 20080279872
    Abstract: The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies.
    Type: Application
    Filed: December 26, 2007
    Publication date: November 13, 2008
    Inventors: Timothy J. O'Brien, Martin J. Cannon, Alessandro Santin, Kristina L. Bondurant
  • Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer
    Publication number: 20080152663
    Abstract: The invention involves peptides of from about 7 to about 50 amino acid residues in length that have epitopes that bind to more than one HLA class II protein and stimulate CD4+ T cells for treatment of cancer from one of three serine proteases overexpressed in ovarian cancer and other cancers—stratum corneum chymotryptic enzyme, matriptase, and hepsin. Since the peptides bind to more than one HLA class II protein variant, they can be used to treat cancer in most patients of a population having a variety of HLA class II alleles. The peptides can be loaded onto autologous dendritic cells of a cancer patient and infused into the patient to activate a CD4+ and CD8+ T cell response that recognizes tumor cells expressing the peptide antigen.
    Type: Application
    Filed: November 21, 2007
    Publication date: June 26, 2008
    Applicant: The Board of Trustees of the University of Arkansas
    Inventors: Martin J. Cannon, Kristina L. Bondurant, Timothy J. O'Brien